AIM-listed Biotech Biz Weighs Dual Listing In Hong Kong
Biotechnology company Allergy Therapeutics, which is listed on the junior investment market of the London Stock Exchange, said Thursday that it's planning a dual primary listing of its shares on the...To view the full article, register now.
Already a subscriber? Click here to view full article